看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
( d4 n1 N$ `9 t- X7 P0 E1 h' L+ F
8 n" g2 D3 C( q/ Z
+ T( S& v& E J9 m" G. rCurrently available feasibility data for possible combination strategies. / Z3 K: }' Y+ D; w" A6 _
———————————————————————————————— u$ a/ [" Z1 l! ~5 W) x8 {
Combination Feasibility according to preliminary data 8 c% h& ^# E' N% Z1 i6 w G* i
——————————————————————————————————
* }0 M( }- w8 ~6 M; w$ LBevacizumab + sorafenib Yes, reduced dose
# x3 j0 S8 `9 h1 K( dBevacizumab + sunitinib† No 5 ]# u! e+ ]: R2 R% F1 s/ B8 w
Bevacizumab + temsirolimus Yes
. w& j! [) z ]: X9 N/ {9 @5 uBevacizumab + everolimus Yes
8 o8 P' t! ] F( n! \9 cSorafenib + sunitinib ?
3 e5 K7 Y* O* E! gSorafenib + temsirolimus Yes, reduced dose
) s/ Q5 `: t4 Y5 D0 VSorafenib + everolimus Yes, reduced dose , t {: t3 |8 _/ Q7 N7 H/ p) Y) k
Sunitinib + temsirolimus† No 2 g( I) m" B4 @. F: H
Sunitinib + everolimus ? " y3 Z) p A1 p* H$ C* [
Temsirolimus + everolimus ?
5 v g9 O% I$ I) D! l- @3 n! q( k————————————————————
; q' D k2 b& J" C! J. l†Led to US FDA warning.
. ]9 J) P5 \. g' _' t$ S?: As yet unattempted combination.
/ J% h/ I2 C' D; f- ~: A$ K |